Skip to content

Clinical-Grade Bioactive Supply

The trusted global supplier of bioactive compounds — built on verified evidence, not promises

mCare provides compounding pharmacies, distributors, and research institutions with clinical-grade bioactive compounds backed by complete documentation — certificates of analysis shipped before product, purity verified at every stage, and sourcing transparency that meets the standard your regulatory environment demands. No chasing paperwork. No potency surprises. Supply infrastructure you can stake your licence on.

Batch Rejection Rate
23%
of compounding batches delayed by supplier documentation gaps
Purity Variance
±4.2%
average potency deviation across unverified bioactive suppliers
Hours Lost Weekly
14hrs
spent chasing COAs, verifying sourcing, and managing supplier gaps
Regulatory Framework 02

The Ground Is Shifting

The regulatory environment is not tightening gradually — it is accelerating. Supply chain certainty is the new baseline.

FDA Classification — 2024

Category 2 peptide classifications now require batch-level documentation that most grey-market suppliers cannot produce. Fourteen additional compounds face potential reclassification by late 2026.

TGA Safety Advisories — April 2026

Australia's Therapeutic Goods Administration issued targeted safety advisories on unapproved peptide products, signalling coordinated international enforcement across APAC and Oceania markets.

CBP Customs Seizure Rates

U.S. Customs and Border Protection seizure rates for undocumented bioactive shipments have increased measurably year-on-year. Shipments without verifiable COAs and traceability records face systematic interception.

State-Level Enforcement Actions

Multiple U.S. states have initiated enforcement actions against compounding pharmacies sourcing from suppliers without audit-ready documentation. The liability chain now extends to procurement decisions.

The Structural Outcome

Suppliers who treated compliance as optional are being systematically removed from the market. For professionals who already operate to high standards, this is the environment they have been waiting for.

Why mCare Exists

Built for a conviction,
not a market gap

The professionals responsible for patient outcomes should never have to second-guess their supply inputs. That conviction is why mCare exists — not as a marketplace, not as another vendor to evaluate, but as upstream supply chain infrastructure purpose-built for regulated environments.

mCare is the upstream bioactive supply partner for licensed distributors, compounding pharmacies, and clinical institutions that require pharmaceutical-grade compounds delivered with batch-level COA documentation, verified cold-chain logistics, and cross-border customs clearance.

  • Verified Upstream Supplier Relationships

    Every compound traces back to a qualified, audited source. We maintain direct relationships with upstream manufacturers — no intermediaries, no ambiguity in provenance.

  • Cross-Border Cold-Chain Logistics

    Temperature-controlled shipments with documented customs clearance across jurisdictions. Every handoff is logged, every condition monitored, every border crossing anticipated.

  • Compliance Documentation Infrastructure

    Proactive documentation that satisfies pharmacopeial, FDA, TGA, and EU standards on every shipment — not retroactively assembled, but built into the fulfilment process from the start.

Professional woman in a business suit participating in a virtual meeting on her laptop, with a bookshelf and a potted orchid in the background - mCare trusted supply chain

Infrastructure, not features

Three operational capabilities define mCare's position. Each is embedded in how we work — not bolted on as an afterthought.

Operational Confidence

Real-Time Shipment Traceability Portal

Live partner-facing visibility into every shipment — temperature logs, delivery status, and documentation readiness — before arrival, not after. Operational confidence built into every consignment.

Proactive Intelligence

Partner Intelligence Briefings

Regulatory alerts delivered before changes affect your operations. We monitor pharmacopeial updates, import rule shifts, and classification changes across jurisdictions so you don't have to.

Structured Pathway

Partner Onboarding Acceleration

A defined pathway from first contact to formalised partnership — with sample evaluation, documentation review, and logistics verification built into the process. No ambiguity, no wasted time.

mCare does not compete on price or catalogue breadth. We compete on the one thing that matters in regulated markets: trust earned batch by batch.

Our Operating Principles

What We Stand For

Not aspirations. Not marketing language. These are the audit criteria every shipment, every COA, and every partnership agreement is built on.

  • Uncompromised Purity

    Every compound meets or exceeds pharmacopeial standards. No exceptions, no tolerance bands, no second-grade alternatives. If it doesn't pass, it doesn't ship.

  • Full Traceability

    Every step from source to delivery is documented and verifiable. Batch-level COAs, temperature logs, chain-of-custody records — available before you ask.

  • Supply Chain Integrity

    Infrastructure, not shortcuts. Cold-chain logistics, qualified warehousing, and redundant sourcing pathways built to withstand disruption — not improvised around it.

  • Professional Trust

    Confidence earned through consistency, not promises. Every partner receives the same standard of documentation, communication, and product quality on every order.

  • Regulatory Alignment

    We operate to the standards that regulated markets demand — as a baseline, not a ceiling. Compliance documentation is built into the process, not bolted on after the fact.

  • Accountability

    If it ships under the mCare name, mCare stands behind it completely. No intermediary excuses. No finger-pointing down the supply chain. Full ownership, every time.

Where to Start

Three pathways, calibrated to your readiness

Trust is earned through evidence, not contracts. Every partnership begins with a conversation and proceeds at the pace your due diligence requires.

For qualified distribution partners

Territory Partnership

Geographic exclusivity, volume-committed pricing, and co-marketing provisions — earned through validated quality assessment. The formalised next step for partners who have proven the relationship.

Discuss Partnership

Beyond the standard catalogue

Custom Sourcing

Non-catalogue compounds sourced, verified, and delivered to your specification — with the same documentation and traceability standards applied to every request, without exception.

Submit a Request

The pathway from first conversation to formalised partnership is structured and transparent. Begin wherever your readiness allows — we will meet you there.